Redesca (low molecular weight heparin biosimilar) / Valeo Pharma - LARVOL DELTA

PRIORITY: Prolonged Hypercoagulability Following Major Liver Resection for Malignancy (clinicaltrials.gov) - P3 | N=50 | Not yet recruiting | Sponsor: Western University, Canada | Initiation date: Feb 2024 ➔ Jun 2024

Trial initiation date • Cardiovascular • Hematological Disorders • Hepatology • Oncology • Thrombosis

PRIORITY: Prolonged Hypercoagulability Following Major Liver Resection for Malignancy (clinicaltrials.gov) - P3 | N=50 | Not yet recruiting | Sponsor: Western University, Canada

New P3 trial • Cardiovascular • Hematological Disorders • Hepatology • Oncology • Thrombosis

Valeo Pharma launches non-brokered private placement of up to 4,000 unsecured non-convertible debentures units at a price of $1,000 (Proactiveinvestors) - "Valeo Pharma Inc. (CSE:VPH) has announced a non-brokered private placement of up to 4,000 unsecured non-convertible debentures units at a price of $1,000 each for maximum gross proceeds of $4 million....'This financing will strengthen our balance sheet at a time of three important product launches for Valeo, Enerzair Breezhaler, Atectura Breezhaler and Redesca. Commercialized through two distinct sales forces, these products are key drivers to our growth over the coming years,' he added."

Financing • Asthma • Respiratory Diseases

"$VPHIF Valeo Pharma Announces Commercial Launch of Redesca™ and Redesca HP™ https://t.co/j6qMMenwAr" (@stock_titan)